Pipeline & Products
Arovella is developing its iNKT cell therapy platform to treat blood cancers and solid tumours.
ALA-101 CD19-targeting CAR-iNKT cells
ALA-101 is a next-generation "off-the-shelf" CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias.
ALA-105 CLDN18.2-targeting CAR-iNKT cells
Arovella has entered into a global, exclusive license with Sparx Group to develop a world-first iNKT cell therapy targeting Claudin 18.2 (CLDN18.2), which is expressed in gastric cancer (GC), gastroesophageal junction cancer (GEJC) and pancreatic cancer (PC).
